<乌鸦传媒>Tranexamic Acid May Hurt Head Trauma Survival for One Key Group Cheap antifibrinolytic given en route to hospital safe overall in registry Dec 07, 2020
<乌鸦传媒>Fixed-Duration Ibrutinib-Venetoclax Promising in First-Line CLL DFS at 1 year reaches 95% in patients with undetectable MRD Dec 06, 2020
<乌鸦传媒>CRISPR-Based Tx Offers Hope in Tough-to-Treat Blood Disorders Success with investigational use of gene editing in sickle cell disease, beta-thalassemia Dec 06, 2020
<乌鸦传媒>Blood Cancers and COVID-19: 'A Medically Vulnerable' Group Patients with hematologic malignancies and SARS-CoV-2 face higher risks for infection, death Dec 06, 2020
<乌鸦传媒>JAK Inhibitor Wins in Second-Line Chronic GVHD Twice as many patients achieved a response at week 24 Dec 05, 2020
<乌鸦传媒>Sickle Cell Disease Tied to Worse COVID-19 Outcomes Black patients seem to be at higher risk for certain COVID-19 complications, death Dec 05, 2020
<乌鸦传媒>Three-Drug Regimen Reduces Myeloma Treatment Burden Efficacy maintained with addition of SQ daratumumab to pomalidomide, dexamethasone Dec 04, 2020
<乌鸦传媒>Bone Marrow Improves Healing With ACL Grafts MRI confirms better outcomes than with allograft alone in randomized study Dec 04, 2020
<乌鸦传媒>Newborns Getting Preoperative Blood Transfusions Have More Complications Data favor restrictive transfusion strategy Oct 22, 2020
<乌鸦传媒>COVID-19 Plus Cancer Proves Deadly Over a third of cancer patients sent to the ICU died Oct 22, 2020
<乌鸦传媒>CDK4/6 Inhibitor in SCLC Cuts Chemo-Induced Myelosuppression Reduced severe neutropenia and less need for supportive care with trilaciclib Oct 20, 2020
<乌鸦传媒>COVID Heart Autopsies Point More to Clot Damage Than Myocarditis Results bolster case for anticoagulation in hospitalized patients Oct 15, 2020
<乌鸦传媒>More Evidence Points to Role of Blood Type in COVID-19 Two studies find ties to infection susceptibility, severity, but with caveats Oct 14, 2020
<乌鸦传媒>Raising the Bar for Myelofibrosis Therapy Development Rational combinations, new targets, and a first-ever phase III trial with a survival endpoint Sep 14, 2020
<乌鸦传媒>New Anemia Linked to Crohn鈥檚 Disease but Not Ulcerative Colitis Risk Anemia seen as promising surrogate marker for preclinical CD, especially in men Sep 11, 2020
<乌鸦传媒>Severe Nosebleeds More Common With Hypertension Korean study supports link between hypertension and epistaxis Sep 10, 2020
<乌鸦传媒>REALITY Check: Stricter RBC Transfusion Safe for Anemic MI Patients Restrictive strategy makes sense for clinical outcomes, costs Sep 01, 2020
<乌鸦传媒>FDA OKs Anti-BCMA Drug for Multiple Myeloma Accelerated approval for belantamab mafodotin after four other therapies Aug 06, 2020
<乌鸦传媒>Skin Rashes a Clue to COVID-19 Vascular Disease Certain skin manifestations tied to coagulopathy in the sickest patients Aug 05, 2020
<乌鸦传媒>COVID-19 More Deadly Than Cancer Itself? Highlights from the AACR conference on COVID-19 and cancer Jul 24, 2020
<乌鸦传媒>The Serious Conversation: Delivering Bad News by Telemedicine As office visits move online, clinicians discuss breaking life-changing diagnoses virtually Jul 13, 2020
<乌鸦传媒>HIV: Don't Quit on Hope, Says 'London Patient' IAC roundtable addresses prospects for cure, now proven to be possible Jul 06, 2020
<乌鸦传媒>Cancer Immunotherapy Tied to Severe COVID-19 Outcomes Nearly threefold increased risk of hospitalization, severe respiratory illness Jun 25, 2020
<乌鸦传媒>Worse Blood Cancer Outcomes in Hispanics Diagnosis at earlier age, worse survival, especially for those on U.S.-Mexico border Jun 24, 2020
<乌鸦传媒>Combination Ups Survival in Older AML Patients Frontline venetoclax plus azacitidine adds 5 months to median OS versus azacitidine alone Jun 17, 2020
<乌鸦传媒>Biologic Effective in Light Chain Amyloidosis Anti-CD38 therapy added to conventional regimen boosts PFS in trial Jun 16, 2020
<乌鸦传媒>Keytruda Tops Adcetris in Head-to-Head Hodgkin's Trial Checkpoint inhibitor improved PFS in refractory and transplant-ineligible cases Jun 15, 2020
<乌鸦传媒>New Standard for Relapsed/Refractory Multiple Myeloma? Triplet regimen significantly extended median PFS versus doublet in IKEMA study Jun 15, 2020
<乌鸦传媒>High Marks for CAR T Cells in R/R Myeloma Response rates of 70-100% with BCMA-targeted products for heavily treated disease Jun 03, 2020
<乌鸦传媒>Early Palliation: Boon for AML Patients on Intensive Chemo Intervention led to marked improvements in QoL, mental distress, end-of-life care Jun 02, 2020
<乌鸦传媒>VRd Still Reigns in Newly Diagnosed Myeloma KRd fails to prove superiority in head-to-head trial Jun 01, 2020
<乌鸦传媒>CAR T-Cell Therapy Impresses in Indolent NHL Overall response rate exceeding 90% with axi-cel in relapsed/refractory setting May 31, 2020
<乌鸦传媒>Nivolumab-Based Tx Effective in Early, Unfavorable Hodgkin's Interim results showed high CR rates and almost 100% PFS, OS at 12 months May 01, 2020
<乌鸦传媒>COVID-19 Mortality Spikes in Patients With Lung, Blood Cancers Those with metastatic disease also at special risk for poor outcomes Apr 28, 2020
<乌鸦传媒>DOAC Works in Cancer-Related VTE, No Tradeoff in Bleeds Apixaban monotherapy matches dalteparin in non-inferiority trial Mar 29, 2020
<乌鸦传媒>Immunotherapy Super-Responder: What Is Life, Not Exactly Cured? Lisa Geller's cancer has been gone nearly 4 years, but life has been far from normal Mar 02, 2020
<乌鸦传媒>Bringing Transplant to More Patients With AML Conditioning with radiolabeled antibody leads to successful transplantation in 84% of older patients Feb 25, 2020
<乌鸦传媒>New CAR-T Makes Case for Aggressive Lymphomas Largest trial to date shows 73% ORR, 53% CR, potential for outpatient treatment Feb 25, 2020
<乌鸦传媒>Stem-Cell Transplant Trial Ends in a Draw Similar PFS with haploidentical bone marrow, double unrelated umbilical cord blood Feb 24, 2020
<乌鸦传媒>Preemptive Anti-IL-6 May Cut Severe CRS With CAR-T Tx Targeting patients with high tumor burden reduced severe CRS by 50% Feb 22, 2020
